Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial

作者：Lisa Leypoldt, Britta Besemer, Anne Marie Asemissen, Mathias Hänel, Igor Wolfgang Blau, Martin Görner, Yon‐Dschun Ko, Hans Christian Reinhardt, Peter Staib, Christoph Mann, Raphael Lutz, Markus Munder, Ullrich Graeven, Rudolf Peceny, Hans Salwender, Anna Jauch, Manola Zago, Axel Benner, Diana Tichy, Carsten Bokemeyer, Hartmut Goldschmidt, Katja Weisel · 发表于：Leukemia · 年份：2021 · DOI：10.1038/s41375-021-01431-x · 被引用次数：77 · 研究领域：Multiple Myeloma Research and Treatments、Protein Degradation and Inhibitors、Peptidase Inhibition and Analysis

The continuous implementation of novel agents in the treatment of multiple myeloma (MM) has led to significant improvement in survival. Especially the addition of monoclonal antibodies directed against CD38 to standard of care regimens led to significantly deepening responses and improved survival outcomes [ 1 ]. However, treatment of high-risk (HR) MM remains challenging with still markedly impaired survival, and risk-adapted treatment concepts are rare [ 2 , 3 ]. Even aggressive approaches resulted in two-year median progression-free survival (PFS) rates of approximately 50% [ 4 ]. The GMMG-CONCEPT trial (NCT03104842) investigates the quadruplet regimen isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of solely HRMM. Here, we report the interim analysis (IA) focusing on best response during induction and presenting first data on PFS of the first 50 patients.